Journal profile · Oncology
Breast Cancer Research and Treatment
ISSN 0167-6806 · eISSN 1573-7217 · Springer US · UNITED STATES · Semimonthly · Founded 1981
Breast Cancer Research and Treatment: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.29; hybrid open access; APC about USD 4,190; median 98 days to acceptance (102 articles, last 24 months); community-reported acceptance: about 25%; 296 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Breast Cancer Research and Treatment is published by Springer US and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Breast Cancer Treatment Studies, Estrogen and related hormone effects and HER2/EGFR in Cancer Research, together about 36.1% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Metapress is an independent digital news organization dedicated to covering the intersection of technology, business, science, and global culture.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology20.2%
- Estrogen and related hormone effectsBiochemistry, Genetics and Molecular Biology8.1%
- HER2/EGFR in Cancer ResearchMedicine7.8%
- Breast Lesions and CarcinomasMedicine7.6%
- BRCA gene mutations in cancerBiochemistry, Genetics and Molecular Biology6.6%
- Cancer Risks and FactorsMedicine6.5%
- Global Cancer Incidence and ScreeningMedicine5.1%
- Cancer Treatment and PharmacologyMedicine4.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.29LetPub ·
- CiteScore 2026-06
- 6.1LetPub ·
- SJR 2026-06
- 1.34LetPub ·
- SNIP 2026-06
- 1.16LetPub ·
- h-index
- 139LetPub ·
- h-index
- 222OpenAlex ·
- i10-index
- 8,865OpenAlex ·
- 2-year mean citedness
- 3.48OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 43.85%LetPub ·
Volume
- Articles per year
- 273LetPub ·
Articles by year OpenAlex count · 12,440 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 204 | 111 | 80 |
| 2025 | 296 | 157 | 707 |
| 2024 | 382 | 225 | 2,284 |
| 2023 | 361 | 218 | 3,416 |
| 2022 | 378 | 205 | 5,606 |
| 2021 | 429 | 203 | 7,611 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
98 daysMedian, submission to acceptance · P25–P75 66 days – 133 days
- Acceptance to online
- median 17 days (102 articles)
- Submission to online
- median 114 days
- Sample
- 102 articles with submission and acceptance dates (587 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 25%LetPub ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,190 / EUR 3,190 / GBP 2,690 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Page charges
- Color art is free of charge for online publication.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Manuscript length
- ≤ 3,500 words
- Reference style
- Numbered, in order of citation
- Templates
- LaTeX and Word
- Suggested reviewers
- Required, 3
- Cover letter
- Required
Article types accepted11, with length limits
- cell line studiesCell Line Studies In general, Breast Cancer Research and Treatment will not accept for publication papers in which all of the data shown in the paper were obtai…Length not stated
- editorialThe journal publishes original laboratory investigations, clinical and translational studies. It also hosts reviews, editorials, and letters. The length of subm…Length not stated
- editorialsThe journal publishes original laboratory investigations, clinical and translational studies. It also hosts reviews, editorials, and letters.Length not stated
- letterThe journal publishes original laboratory investigations, clinical and translational studies. It also hosts reviews, editorials, and letters. The length of subm…Length not stated
- letter to the editorThe journal publishes original laboratory investigations, clinical and translational studies. It also hosts reviews, editorials, and letters. The length of subm…main text ≤ 750 words · figures and tables ≤ 1 · references ≤ 3
- lettersThe journal publishes original laboratory investigations, clinical and translational studies. It also hosts reviews, editorials, and letters.Length not stated
- meta-analysisThe journal publishes original laboratory investigations, clinical and translational studies. It also hosts reviews, editorials, and letters. The length of subm…Length not stated
- newsNews Technology Business Entertainment Science / Health Partner ContentLength not stated
- reviewThe journal publishes original laboratory investigations, clinical and translational studies. It also hosts reviews, editorials, and letters. The length of subm…Length not stated
- reviewsThe journal publishes original laboratory investigations, clinical and translational studies. It also hosts reviews, editorials, and letters.Length not stated
- tumor marker studiesTumor Marker Studies Manuscript describing the results of tumor marker studies should include the essential elements of "Reporting recommendations for tumor mar…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Preprints, Trial registration / reporting guidelines
- AI use Generative AI Images
Large Language Models (LLMs), such as ChatGPT, do not currently satisfy the journal's authorship criteria. Model summary
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
Authors are highly recommended to provide academic email addresses instead of personal ones. Model summary
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data Availability
All original research must include a Data Availability Statement. Data Availability Statements should provide information on where data supporting the results reported in the article can be found. Statements should include, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. When it is not possible to share research data publicly, for instance when in…
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
The corresponding author must provide an ORCiD ID before proceeding with submission. Model summary
To find out more about publishing your work Open Access in Breast Cancer Research and Treatment, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review
Authors must suggest at least three possible reviewers without conflict of interest in the Cover Letter upon submission. Model summary
Note: Authors must suggest at least three possible reviewers without conflict of interest in the Cover Letter upon submission.
Source ↗Publisher website ·- Preprints
Submissions of review and meta-analyses papers require pre-approval by the Editor. Model summary
Submissions of review and meta-analyses papers require pre-approval by the Editor.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer US
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Semimonthly
- Founded
- 1981
- ISSN
- 0167-6806
- Electronic ISSN
- 1573-7217
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Breast Cancer Research and Treatment
What CAS zone is Breast Cancer Research and Treatment in?
In the 2025 upgraded edition of the CAS Journal Ranking, Breast Cancer Research and Treatment is in Zone 3 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Breast Cancer Research and Treatment?
The latest impact factor listed by LetPub is 3.29; CiteScore 6.1, h-index 222.
How long does peer review take at Breast Cancer Research and Treatment?
Based on the dates recorded on 102 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 98 days (interquartile range 66–133 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 25%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Breast Cancer Research and Treatment?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Manuscript length: ≤ 3,500 words; Reference style: Numbered, in order of citation; Templates: LaTeX and Word; Suggested reviewers: Required, 3; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Breast Cancer Research and Treatment?
According to LetPub and DOAJ records, Breast Cancer Research and Treatment is indexed in SCIE and Scopus.
Is Breast Cancer Research and Treatment open access, and what is the APC?
Breast Cancer Research and Treatment is a hybrid journal. For open-access publication: APC about USD 4,190.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .